Original Study| Volume 14, ISSUE 4, P323-330, August 2016

A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings

Published:August 06, 2015DOI:



      The role of chemotherapy in nodal metastases from penile squamous cell carcinoma is not defined. We evaluated the efficacy of a combination of T-PF (a taxane, cisplatin, and 5-fluorouracil) in neoadjuvant and adjuvant settings.

      Patients and Methods

      Since June of 2004, T-PF was administered to stage N2 to 3 patients. With time, neoadjuvant chemotherapy administration prevailed with respect to use in the adjuvant setting. Primary end points were progression-free (PFS) and overall (OS) survival. Secondary objectives were tolerability and activity in the neoadjuvant setting. Nonparametric tests, Kaplan–Meier, and regression analyses were performed.


      As of October of 2012, 47 consecutive N2 to 3 M0 patients had undergone neoadjuvant (n = 28) or adjuvant (n = 19) T-PF: 18 patients (38.3%) remain disease-free after a median follow-up of 22 months (interquartile range, 17-42 months). The 2-year disease-free survivals were 36.8% (95% confidence interval [CI], 15.2-58.5) versus 7.1% (95% CI, 0-16.7) after adjuvant and neoadjuvant therapy, respectively. N3 metastases were associated with a poorer PFS, and bilateral metastases and mutated p53 were associated with a poorer OS. After neoadjuvant treatment, 43% clinical responses and 14% complete pathologic remissions were recorded, but responses were not associated with survival. Neutropenia (25.5%) was the most frequent Grade ≥ 2 toxicity.


      The T-PF regimen is well tolerated and compares with other regimens in terms of activity and efficacy in the neoadjuvant setting, and very long survivals have been recorded after adjuvant administration. The role of perioperative treatment in these patients remains controversial. Some caution in administering preemptive treatment in patients with resectable disease is needed.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Barnholtz-Sloan J.S.
        • Maldonado J.L.
        • Pow-sang J.
        • Giuliano A.R.
        Incidence trends in primary malignant penile cancer.
        Urol Oncol. 2007; 25: 361-367
        • Ornellas A.A.
        Management of penile cancer.
        J Surg Oncol. 2008; 97: 199-200
        • Protzel C.
        • Alcaraz A.
        • Horenblas S.
        • Pizzocaro G.
        • Zlotta A.
        • Hakenberg O.W.
        Lymphadenectomy in the surgical management of penile cancer.
        Eur Urol. 2009; 55: 1075-1088
      1. Hakenberg OW, Compérat E, Minhas S, Necchi A, Protzel C, Watkin N. EAU penile cancer guidelines 2014. Available at: Accessed August 16, 2014.

        • Pizzocaro G.
        • Piva L.
        Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis.
        Acta Oncol. 1988; 27: 823-824
        • Shammas F.V.
        • Ous S.
        • Fossa S.D.
        Cisplatin and 5-fluorouracil in advanced cancer of the penis.
        J Urol. 1992; 147: 630-632
        • Dexeus F.H.
        • Logothetis C.J.
        • Sella A.
        • et al.
        Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract.
        J Urol. 1991; 146: 1284-1287
        • Haas G.P.
        • Blumenstein B.A.
        • Gagliano R.G.
        • et al.
        Cisplatin,methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study.
        J Urol. 1999; 161: 1823-1825
        • Corral D.A.
        • Sella A.
        • Pettaway C.A.
        • Amato R.J.
        • Jones D.M.
        • Ellerhorst J.
        Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin.
        J Urol. 1998; 160: 1770-1774
        • Theodore C.
        • Skoneczna I.
        • Bodrogi I.
        • et al.
        A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC 30992).
        Ann Oncol. 2008; 19: 1304-1307
        • Leijte J.A.
        • Kerst J.M.
        • Bais E.
        • Antonini N.
        • Horenblas S.
        Neoadjuvant chemotherapy in advanced penile carcinoma.
        Eur Urol. 2007; 52: 488-494
        • Hakenberg O.W.
        • Nippgen J.B.
        • Froehner M.
        • Zastrow S.
        • Wirth M.P.
        Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma.
        BJU Int. 2006; 98: 1225-1227
        • Hitt R.
        • López-Pousa A.
        • Martínez-Trufero J.
        • et al.
        Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
        J Clin Oncol. 2005; 23: 8636-8645
        • Vermorken J.B.
        • Remenar E.
        • van Herpen C.
        • et al.
        Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
        N Engl J Med. 2007; 357: 1695-1704
        • Posner M.R.
        • Hershock D.M.
        • Blajman C.R.
        • et al.
        Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
        N Engl J Med. 2007; 357: 1705-1715
        • Pizzocaro G.
        • Nicolai N.
        • Milani A.
        Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results.
        Eur Urol. 2009; 55: 546-551
        • Pagliaro L.C.
        • Williams D.L.
        • Daliani D.
        • et al.
        Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
        J Clin Oncol. 2010; 28: 3851-3857
        • Nicholson S.
        • Hall E.
        • Harland S.J.
        • et al.
        Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001).
        Br J Cancer. 2013; 109: 2554-2559
      2. National Cancer Institute. CTEP. Common terminology criteria for adverse events, v. 4.0. Available at: Accessed August 20, 2013.

        • Pizzocaro G.
        • Piva L.
        • Nicolai N.
        Lymphadenectomy for cancer of the penis.
        in: Donohue J.P. Lymph Node Surgery in Urology. Isis Media Limited, Oxford1995: 118-130
      3. Response Evaluation Criteria In Solid Tumors, v. 1.1. Available at: Accessed August 20, 2013.

        • Perrone F.
        • Bossi P.
        • Cortelazzi B.
        • et al.
        TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
        J Clin Oncol. 2010; 28: 761-766
        • Winters R.
        • Trotman W.
        • Adamson C.S.
        • et al.
        Screening for human papillomavirus in basaloid squamous carcinoma: utility of p16INK4a, CISH, and PCR.
        Int J Surg Pathol. 2011; 19: 309-314
        • Kaplan E.L.
        • Meier P.
        Nonparametric estimation from incomplete observations.
        J Am Stat Assoc. 1958; 53: 457-481
        • Hollander M.
        • Wolfe D.A.
        Nonparametric Statistical Methods.
        2nd ed. John Wiley & sons, New York1999
        • Agresti A.
        Categorical Data Analysis.
        2nd ed. John Wiley & sons, New York2002
      4. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: Accessed April 15, 2013.

      5. NCCN Clinical Practice Guidelines in Oncology: Penile Cancer. v. 1.2014. Available at: Accessed August 16, 2014.

        • Pizzocaro G.
        • Piva L.
        • Bandieramonte G.
        • Tana S.
        Up-to-date management of carcinoma of the penis.
        Eur Urol. 1997; 32: 5-15
        • Bermejo C.
        • Busby J.E.
        • Spiess P.E.
        • Heller L.
        • Pagliaro L.C.
        • Pettaway C.A.
        Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma.
        J Urol. 2007; 177: 1335-1338
        • Zhu Y.
        • Li H.
        • Yao X.D.
        • et al.
        Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report.
        Urol Int. 2010; 85: 334-340
        • Necchi A.
        • Nicolai N.
        • Colecchia M.
        • et al.
        Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis.
        J Clin Oncol. 2011; 29: e650-e652
        • Franks K.N.
        • Kancherla K.
        • Sethugavalar B.
        • Whelan P.
        • Eardley I.
        • Kiltie A.E.
        Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals.
        J Urol. 2011; 186: 524-529